Ridge Diagnostics Depression Blood Test Biomarker Technology featured in Cover Story of Psychiatric Times

MDDScoreTM, Ridge Diagnostics depression blood test biomarker technology, featured in cover story “Blood Tests for Diagnosis of Schizophrenia and Depression?”

San Diego (PRWEB) August 11, 2011 -- Ridge Diagnostics, a San Diego-based neurodiagnostic company offering the first blood test for depression, is proud to announce that its depression blood test biomarker technology, the MDDScore, was featured as part of the cover story in Psychiatric Times, August 2011, Volume XXVIII, No 8.

The story, “Blood Tests for Diagnosis of Schizophrenia and Depression?” was based on clinical research reported at the 164th American Psychiatric Association Annual Meeting held in Honolulu, HI, May 14-18, 2011. The article presented three companies and technologies.

In a quotation from the article, Lonna J. Williams, CEO of Ridge stated, "By having a biological indication of depression, patients and their families have a better understanding of the condition as a medical one, which reduces the stigma of mental health disorders and leads to an improvement in treatment compliance."

A simple blood test may also greatly assist primary care physicians in distinguishing Major Depressive Disorder from other conditions with overlapping symptoms, like fatigue and energy loss.

Ridge offers a proprietary, simple blood test for Major Depressive Disorder (MDD) through its CLIA-certified laboratory. Ridge researches, develops, and brings to healthcare providers and patients a blood test based on biological markers and diagnostic algorithms to aid in with the diagnosis of MDD and other neuropsychiatric disorders.

For more information on Ridge Diagnostics technology and MDDScore, visit Ridgedx.com. To receive a copy of the APA presentation, request: Improving the Diagnosis of Major Depressive Disorder: A New Multi-Analyte Biomarker Panel and MDDScore from Ridgedx.com.

ABOUT RIDGE DIAGNOSTICS, INC.
Ridge Diagnostics is a neurodiagnostic company that develops and markets blood-based tests to diagnose and monitor neuropsychiatric disorders. Ridge has commercialized the first-in-class, proprietary blood test for the diagnosis and treatment monitoring of Major Depressive Disorder (MDD). The portfolio of neurodiagnostic blood tests are based on a proprietary Human Biomarker Library and Hyper-Mapping technology. The testing services are provided by the Ridge owned CLIA laboratory. The company is located in San Diego and Research Triangle Park, N.C.

###
Contact Information
Catherine Schuster
Ridge Diagnostics
http://ridgedx.com/
858-997-2593

Online Web 2.0 Version
You can read the online version of this press release here.